Get started
Author

Paulo Lúcio

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
2017 · María-Victoria Mateos, Meletios A. Dimopoulos, et al. · New England Journal of Medicine · 1,004
PDF
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
2012 · J J M van Dongen, L Lhermitte, et al. · Leukemia · 955
PDF
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
2019 · Maria-Victoria Mateos, Michele Cavo, et al. · The Lancet · 460
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
2019 · Paul G Richardson, Albert Oriol, et al. · The Lancet Oncology · 388
Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL
1999 · P Lúcio, A Parreira, et al. · Leukemia · 234
Quality assessment program for E uro F low protocols: Summary results of four‐year (2010–2013) quality assurance rounds
2014 · Tomas Kalina, Juan Flores‐Montero, et al. · Cytometry Part A · 144
PDF
BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings
2001 · P Lucio, G Gaipa, et al. · Leukemia · 137
Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions.
1999 · A Orfao, G Schmitz, et al. · PubMed · 123
BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)
2000 · A Porwit-MacDonald, E Björklund, et al. · Leukemia · 122
Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies.
2004 · Clara Bueno, Julia Almeida, et al. · PubMed · 121
Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia
2013 · L R Martins, P Lúcio, et al. · Leukemia · 76
Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients
2009 · F Weerkamp, E Dekking, et al. · Leukemia · 74
Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia
2010 · Leila R. Martins, Paulo Lúcio, et al. · Blood · 70
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
2021 · Maria-Victoria Mateos, Meletios A. Dimopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia · 59
PDF
Effects of Delta1 and Jagged1 on Early Human Hematopoiesis: Correlation with Expression of Notch Signaling‐Related Genes in CD34 + Cells
2006 · Hélia Neves, Floor Weerkamp, et al. · Stem Cells · 44
PDF
Expression of adhesion molecules in chronic B-cell lymphoproliferative disorders.
1998 · P J Lúcio, M T Faria, et al. · PubMed · 41
Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor
2013 · Leila R. Martins, Yasser Perera, et al. · Oncotarget · 36
PDF
CD123 hiDendritic Cell Lymphoma: An Unusual Case of Non-Hodgkin Lymphoma
1999 · Paulo Lúcio, Antonio Parreira, et al. · Annals of Internal Medicine · 35
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
2025 · Maria-Victoria Mateos, Jesus San-Miguel, et al. · The Lancet Oncology · 34
Flow cytometric immunobead assay for fast and easy detection of PML–RARA fusion proteins for the diagnosis of acute promyelocytic leukemia
2012 · E H A Dekking, V H J van der Velden, et al. · Leukemia · 32
PDF
Evaluation of Semiautomatic and Deep Learning–Based Fully Automatic Segmentation Methods on [18F]FDG PET/CT Images from Patients with Lymphoma: Influence on Tumor Characterization
2023 · Cláudia S. Constantino, Sónia Leocádio, et al. · Journal of Imaging Informatics in Medicine · 31
PDF
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
2019 · Maria-Victoria Mateos, Michele Cavo, et al. · Blood · 25
Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay
2010 · E. Dekking, V.H.J. van der Velden, et al. · Best Practice & Research Clinical Haematology · 25
PDF
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
2021 · Stefan Knop, Maria-Victoria Mateos, et al. · BMC Cancer · 24
PDF
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness
2021 · Manuel Neves, Fernanda Trigo, et al. · PharmacoEconomics · 24
PDF
Works count: 73
Citation count: 4,561
H-index: 24
I10-index: 36
Year
Topic
Type